Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era

被引：1
作者：
Van Cutsem, Eric [1 ]
Tejpar, Sabine [1 ]
机构：
[1] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Leuven, Belgium
来源：
TARGETED ONCOLOGY | 2008年 / 3卷 / 04期
关键词：
Predictive markers; Colorectal cancer; EGFR; Targeted therapy;
D O I：
10.1007/s11523-008-0097-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：223 / 225
页数：3
相关论文
共 23 条
[1]  
AMADO R, 2008, J CLIN ONCOL, V26, P1582
[2]   Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].
Benvenuti, Silvia ;
Sartore-Bianchi, Andrea ;
Di Nicolantonio, Federica ;
Zanon, Carlo ;
Moroni, Mauro ;
Veronese, Silvio ;
Siena, Salvatore ;
Bardelli, Alberto .
CANCER RESEARCH, 2007, 67 (06) :2643-2648
[3]  
BOCKEMEYER C, 2008, ASCO ANN M 2008
[4]   EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients [J].
Cappuzzo, F. ;
Finocchiaro, G. ;
Rossi, E. ;
Jaenne, P. A. ;
Carnaghi, C. ;
Calandri, C. ;
Bencardino, K. ;
Ligorio, C. ;
Ciardiello, F. ;
Pressiani, T. ;
Destro, A. ;
Roncalli, M. ;
Crino, L. ;
Franklin, W. A. ;
Santoro, A. ;
Varella-Garcia, M. .
ANNALS OF ONCOLOGY, 2008, 19 (04) :717-723
[5]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345
[6]   KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab [J].
De Roock, W. ;
Piessevaux, H. ;
De Schutter, J. ;
Janssens, M. ;
De Hertogh, G. ;
Personeni, N. ;
Biesmans, B. ;
Van Laethem, J. -L. ;
Peeters, M. ;
Humblet, Y. ;
Van Cutsem, E. ;
Tejpar, S. .
ANNALS OF ONCOLOGY, 2008, 19 (03) :508-515
[7]   Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy [J].
Di Fiore, F. ;
Blanchard, F. ;
Charbonnier, F. ;
Le Pessot, F. ;
Lamy, A. ;
Galais, M. P. ;
Bastit, L. ;
Killian, A. ;
Sesboue, R. ;
Tuech, J. J. ;
Queuniet, A. M. ;
Paillot, B. ;
Sabourin, J. C. ;
Michot, F. ;
Michel, P. ;
Frebourg, T. .
BRITISH JOURNAL OF CANCER, 2007, 96 (08) :1166-1169
[8]  
DIFIORE F, 2008, ANN ONCOL S6, V19
[9]   PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients [J].
Frattini, M. ;
Saletti, P. ;
Romagnani, E. ;
Martin, V. ;
Molinari, F. ;
Ghisletta, M. ;
Camponovo, A. ;
Etienne, L. L. ;
Cavalli, F. ;
Mazzucchelli, L. .
BRITISH JOURNAL OF CANCER, 2007, 97 (08) :1139-1145
[10]   Cetuximab for the treatment of colorectal cancer [J].
Jonker, Derek J. ;
O'Callaghan, Chris J. ;
Karapetis, Christos S. ;
Zalcberg, John R. ;
Tu, Dongsheng ;
Au, Heather-Jane ;
Berry, Scott R. ;
Krahn, Marianne ;
Price, Timothy ;
Simes, R. John ;
Tebbutt, Niall C. ;
van Hazel, Guy ;
Wierzbicki, Rafal ;
Langer, Christiane ;
Moore, Malcolm J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (20) :2040-2048
123